Key result
Pimobendan administration was associated with a significantly longer median survival time (626 days) compared to treatment without pimobendan (103 days) in cats with CHF secondary to HCM or HOCM.
Why the study?
Does pimobendan improve survival time in cats with congestive heart failure secondary to hypertrophic cardiomyopathy?
Case-Control (n=54)
Does pimobendan improve survival time in cats with congestive heart failure secondary to hypertrophic cardiomyopathy?
The addition of pimobendan to traditional treatment for CHF provides a substantial survival benefit in cats with HCM or HOCM.
Answers are grounded in this paper and cite their sources.
May support pimobendan in cats with HCM-related CHF; hypothesis-generating and requires randomized trials before practice change.
OBJECTIVE: To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM). DESIGN: Retrospective case-control study. ANIMALS: 27 cats receiving treatment with pimobendan and 27 cats receiving treatment without pimobendan. PROCEDURES: Medical records between 2003 and 2013 were reviewed. All cats with HCM or HOCM treated with a regimen that included pimobendan (case cats) were identified. Control cats (cats with CHF treated during the same period with a regimen that did not include pimobendan) were selected by matching to case cats on the basis of age, sex, body weight, type of cardiomyopathy, and manifestation of CHF. Data collected included signalment, physical examination findings, echocardiographic data, serum biochemical values, and survival time from initial diagnosis of CHF. Kaplan-Meier survival curves were constructed and compared by means of a log rank test. RESULTS: Cats receiving pimobendan had a significant benefit in survival time. Median survival time of case cats receiving pimobendan was 626 days, whereas median survival time for control cats not receiving pimobendan was 103 days. No significant differences were detected for any other variable. CONCLUSIONS AND CLINICAL RELEVANCE: The addition of pimobendan to traditional treatment for CHF may provide a substantial clinical benefit in survival time for HCM-affected cats with CHF and possibly HOCM-affected cats with CHF.
No takes yet. Share an insight, caveat, or question.
Reina‐Doreste et al. (2014) conducted a case-control in Congestive heart failure secondary to hypertrophic cardiomyopathy or hypertrophic obstructive cardiomyopathy (n=54). Pimobendan vs. Treatment without pimobendan was evaluated on Survival time. Pimobendan administration was associated with a significantly longer median survival time (626 days) compared to treatment without pimobendan (103 days) in cats with CHF secondary to HCM or HOCM.
Synapse has enriched 10 related papers. Consider them for comparative context: